TallyHQ
github
Client · LDA

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

5 filings 14 bills mentioned 1 registrants 5 quarters ~$260,000 reported
Client ID
192228

Bills lobbied on

Bills referenced in this client's quarterly filings, ranked by filing count.

S 891
Bipartisan Health Care Act
HCR
5
S 527
Prescription Pricing for the People Act of 2025
HCR
5
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HCR
5
S 1041
Affordable Prescriptions for Patients Act
HCR
5
S 1097
Interagency Patent Coordination and Improvement Act of 2025
HCR
5
S 1040
Drug Competition Enhancement Act
HCR
5
S 1095
Stop STALLING Act
HCR
5
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
MMM
4
S 832
EPIC Act of 2025
MMM
4
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
BUDMMM
3
S 2296
National Defense Authorization Act for Fiscal Year 2026
HCRTRD
2
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
HCRTRD
2
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
BUD
1
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
BUD
1

Registrants

Lobbying firms that filed on behalf of this client.

CROSSROADS STRATEGIES, LLC 5

Source: Senate LDA quarterly filings (LD-2). Bill mentions extracted from free-text "specific issues" descriptions.